The role of glucose in cognition, risk of dementia, and related biomarkers in individuals without type 2 diabetes mellitus or the metabolic syndrome: A systematic review of observational studies

Neurosci Biobehav Rev. 2022 Apr:135:104551. doi: 10.1016/j.neubiorev.2022.104551. Epub 2022 Jan 29.

Abstract

Background: Excessive blood glucose promotes neuropathological cognitive decline in individuals with type 2 diabetes mellitus and the metabolic syndrome, but no systematic synthesis of the evidence for the same association exists in individuals without these conditions.

Objectives: To systematically review studies exploring the role of glucose on cognition, dementia risk, and related biomarkers in adults without diabetes or metabolic syndrome.

Data sources: We searched databases from inception until July 2021 and manually searched the reference lists of included studies. Risk of bias was assessed using the Joanna Briggs Institute tool.

Results: We found 46 observational studies including approximately 98,216 participants. Substantial heterogeneity in study results precluded drawing definitive conclusion whether blood glucose levels are associated with cognition or dementia risk. Higher blood glucose, however, was associated with greater amyloid burden, brain atrophy, and reduced cortical thickness.

Conclusions and implications: High glucose concentrations in blood may exacerbate dementia-related neuropathology but whether this translates into pathological cognitive decline or elevate dementia risk later in life remains unclear.

Keywords: Beta-amyloid; Cognition; Dementia; Glucose; Neurodegeneration; Sugar.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Biomarkers
  • Cognition
  • Cognitive Dysfunction* / complications
  • Dementia* / complications
  • Diabetes Mellitus, Type 2* / complications
  • Glucose
  • Humans
  • Metabolic Syndrome* / complications

Substances

  • Biomarkers
  • Glucose